$1.43
4.36% today
NYSE, Apr 02, 09:21 pm CET
ISIN
US44486Q1031
Symbol
HUMA
Sector
Industry

Humacyte Stock price

$1.49
-1.57 51.23% 1M
-4.01 72.88% 6M
-3.56 70.50% YTD
-1.52 50.50% 1Y
-5.66 79.16% 3Y
-8.18 84.59% 5Y
-8.18 84.59% 10Y
NYSE, Closing price Tue, Apr 01 2025
-0.22 12.61%
ISIN
US44486Q1031
Symbol
HUMA
Sector
Industry

Key metrics

Market capitalization $191.72m
Enterprise Value $227.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-114.40m
Free Cash Flow (TTM) Free Cash Flow $-99.69m
Cash position $45.08m
EPS (TTM) EPS $-1.26
P/E forward negative
P/S forward 22.73
EV/Sales forward 26.92
Short interest 26.64%
Show more

Is Humacyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Humacyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Humacyte forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Humacyte forecast:

Buy
86%
Hold
14%

Financial data from Humacyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 7.23 7.23
18% 18%
-
-7.23 -7.23
18% 18%
-
- Selling and Administrative Expenses 11 11
90% 90%
-
- Research and Development Expense 89 89
16% 16%
-
-107 -107
17% 17%
-
- Depreciation and Amortization 7.23 7.23
18% 18%
-
EBIT (Operating Income) EBIT -114 -114
14% 14%
-
Net Profit -149 -149
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Humacyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Humacyte Stock News

Neutral
Seeking Alpha
5 days ago
Humacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Josh Jennings - TD Cowen & Company Ryan Zimmerman - BTIG Vernon Bernardino - H.C. Wainwrigh...
Neutral
GlobeNewsWire
5 days ago
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -
Neutral
GlobeNewsWire
7 days ago
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2024, on Friday, March 28, 2025.
More Humacyte News

Company Profile

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Head office United States
CEO Laura Niklason
Employees 220
Founded 2004
Website humacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today